Remarkable new research by a University of Virginia undergraduate may help explain recurrent Crohn’s disease in children and open the door to new ways to treat or even cure the devastating condition.
Lava Therapeutics makes cuts to its headcount
Lava Therapeutics said Tuesday that it cut 36% of its staff after the biotech stopped all work on a therapy looking to go after CD1d-expressing